Published on 28 Feb 2024 on GuruFocus.com via Yahoo Finance

Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023

Revenue: Reported a decrease to $13.0 million in Q4 and $51.1 million for the full year, compared to the previous year.Net Loss: Increased net loss to $28.0 million in Q4 and $93.8 million for the full year.Research and Development Expenses: R&D expenses rose to $35.3 million in Q4 and $133.6 million for the full year.General and Administrative Expenses: G&A expenses slightly increased to $8.6 million in Q4 and $33.8 million for the full year.Liquidity Position: Cash, cash equivalents, and marketable securities totaled $223.6 million as of December 31, 2023.Operational Milestones: Advanced clinical programs and received a $40 million milestone payment from Roche.Collaboration Termination: Roche to terminate collaboration agreement with Repare in May 2024.

Warning! GuruFocus has detected 4 Warning Signs with RPTX.

On February 28, 2024, Repare Therapeutics Inc (NASDAQ:RPTX) released its 8-K filing, detailing the financial results for the fourth quarter and the full year ended December 31, 2023. The precision oncology company, which specializes in developing synthetic lethality-based therapies for cancer patients, has reported a year of significant clinical progress despite facing financial headwinds.